Former President of the College of Naturopathic Physicians of British Columbia Joins StillCanna’s Team

Vancouver, British Columbia – (PR Newswire) – Thursday, May 16, 2019 – StillCanna Inc. (CSE: STIL) (“STIL” or the “Company”) is pleased to announce that Dr. Brian Martin, ND has joined the StillCanna Team. Dr. Martin brings a wealth of knowledge and experience, including but not limited to:

  • 25 years practicing Naturopathic Medicine;
  • the formulation of innovative natural health products;
  • former President of the College of Naturopathic Physicians of British Columbia; and
  • Expert in Optimal Aging from the American Academy of Anti-Aging Medicine.

Dr. Martin will lead the Company’s consumer and Nutraceutical and Cosmeceutical product formulations with the goal of enhancing the natural capabilities of CBD and other therapeutic cannabinoids, including terpenes and other organic compounds. He will be the Company’s medical representative for industry research, speaking engagements and product formulations. Dr. Martin will evaluate the current Olimax product line and expects to formulate new CBD related products with a special focus on the expanding nutritional (food and beverages) and wellness marketplaces. Particular attention will be directed towards the female market, along with matters related to the improvement of quality of life, including products aiming to enhance energy, mood, memory, libido and athletic performance.

“Dr. Martin has dedicated his life to the proactive empowerment of the modern consumer, and has developed substantial practical experience and knowledge of the current health needs of both men and women” exclaimed Jason Dussault Chief Executive Officer of StillCanna. “We anticipate that his practical knowledge and capabilities will make StillCanna’s CBD products increasingly effective and metabolically friendly compared to other products currently available in the market. Dr. Martin will work with the Company part time for the next 2 quarters with an eye towards full time employment as we expand our product vision.”

“I have been very impressed with some of the proprietary techniques and technologies StillCanna has relating to the production and formulation of various CBD products,” stated Dr. Martin. “StillCanna’s vision of CBD in the wellness and the global Nutraceutical market is in line with the types of CBD products I envision. StillCanna’s CEO has strong branding and marketing skills which, coupled with my formulation skills, paints a very exciting picture.”

As partial compensation for the engagement of Dr. Martin, the Company will grant 200,000 incentive stock options to Dr. Martin with an exercise price equivalent to a 5% premium to the closing price of the Company’s common shares on the date of grant.

Further to its press release dated May 7, 2019, the Company has also issued 850,000 common shares to certain finders in connection with the acquisition of Olimax. As a result, an aggregate of 1,300,000 common shares have been issued to finders in connection with the acquisition of Olimax.

About StillCanna Inc.

StillCanna Inc. (CSE: STIL) www.StillCanna.com is a Canadian early-stage life sciences company focused on large scale CBD extraction in Europe.  The Company feels its proprietary intellectual property allows it to extract CBD at a lower cost. The Company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. The Company also recently completed the acquisition of Olimax NT SP. Z .O.O, which is expected to increase the Company’s market share in the European CBD industry.

 On Behalf of the Board,
Jason Dussault,
Chief Executive Officer and Director
Email: info@stillcanna.com
Phone: 604-239-0840

Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the enhancement of the natural capabilities of CBD and other therapeutic cannabinoids, the formulation of new CBD related products, including products to enhance energy, mood, memory, libido and athletic performance, the increased effectiveness and metabolic friendliness of the Company’s products and the hiring of Dr. Martin as a full time employee of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the Company will be able to enhance the natural capabilities of CBD and other therapeutic cannabinoids, that the Company will be able to formulate new CBD related products, including products to enhance energy, mood, memory, libido and athletic performance, that the Company will be able to increase the effectiveness and metabolic friendliness of the its products and that the Company will be able to hire Dr. Martin as a full time employee of the Company. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, that the Company will not be able to enhance the natural capabilities of CBD and other therapeutic cannabinoids, that the Company will not be able to formulate new CBD related products, including products to enhance energy, mood, memory, libido and athletic performance, that the Company will not be able to increase the effectiveness and metabolic friendliness of the its products and that the Company will not be able to hire Dr. Martin as a full time employee of the Company. Readers are cautioned not to place undue reliance on forward-looking statements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Stillcanna Acquires Polish Hemp Producer and Receives the Proceeds of Its $24,365,000 Financing

Vancouver, British Columbia–(Newsfile Corp. – May 7, 2019) – STILLCANNA INC. (CSE: STIL) (“StillCanna” or the “Company”) the Company is pleased to announce that further to the Company’s press release dated March 18, 2019, the Company successfully acquired 100% of Olimax’s issued and outstanding shares.

The acquisition of Olimax provides Stillcanna with a vertically integrated licensed cultivator, extractor and formulator of CBD. One of Olimax’s many core strengths is its agriculture expertise with hemp.

The founders of Olimax Zofia Valber and Krystyna Bojeck have taken on the roles of VP Operations Poland and will oversee the day-to-day management of the Company’s Polish operations. With over 40 years combined experience in hemp products, their accomplishments include a patented microelement fertilizer and the germination and registration of an EU certified propriety varietal of high CBD content hemp. Zofia and Krystyna have decades of hemp production and product formulations along with degrees in agriculture and chemistry.

The Company is seeding its 1500 hectares of land in Poland with the Company’s proprietary hemp varietal and expects its harvest to be in early August.

“This acquisition uniquely positions Stillcanna in the supply chain of wholesale CBD in Europe,” pointed out Jason Dussault Chief Executive Officer of StillCanna, “there is global interest in sourcing a reliable flow of wholesale CBD in Europe and StillCanna is now in a position to address that global interest.”

The purchase price of Olimax consists of 24,000,000 common shares and $2,000,000 in cash. 20,064,000 of the 24,000,000 shares are subject to a contractual restriction on trading whereby 1/12 of the shares will be released from such contractual restriction every three months from the date of issuance and all of the shares are subject to a four-month and a day hold period from the date of issuance, in accordance with applicable Canadian securities laws.

As previously announced on April 25, 2019, the Company completed a financing of an aggregate of 21,187,587 subscription receipts at a price of $1.15 per subscription receipt for aggregate gross proceeds of approximately $24,365,000 with Canaccord Genuity Corp. as agent. The net proceeds of the financing were released to the Company in connection with the satisfaction of the escrow release conditions by the Company through its successful acquisition of Olimax. The subscription receipts automatically converted into one common share of the Company and one-half of one common share purchase warrant. Each warrant is exercisable to acquire one common share for a period of 12 months at an exercise price of $1.73.

The Company intends to use the net proceeds of the Offering to expand its CBD processing capacity at the Company’s facility in Romania, to build out Olimax’s CBD extraction facility and agricultural capabilities in Poland along with working capital and general corporate expenditures.

In connection with the acquisition of Olimax, the Company issued 450,000 common shares to certain finders. It also issued 700,000 common shares to certain consultants in exchange for financial advisory services.

ABOUT STILLCANNA INC.

StillCanna Inc. (CSE: STIL) (www.stillcanna.com) is a Canadian early-stage life sciences company focused on large-scale CBD extraction in Europe. Based on a proprietary process and intellectual property, the Company is forecasted to be one of the lowest-cost CBD extractors operating in Europe. The Company has signed an extraction contract to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. With the completion of the Olimax Transaction, StillCanna is one of the leading processors and providers of market-ready CBD in Europe.

On Behalf of the Board,

Joel Leonard,
Chief Financial Officer and Director
E-mail: joel@stillcanna.com
Phone: 778-838-3692

The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release.

Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the expected harvest date of the Company’s 1,500 hectares of land being in early August. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the cultivation of the Company’s hemp will be successful and the harvest date of the Company’s 1,500 hectares of land will be in early August as anticipated by management of the Company. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, that the cultivation of the Company’s hemp will not be successful or will be delayed and the harvest date of the Company’s 1,500 hectares of land will not be in early August or at all. Readers are cautioned not to place undue reliance on forward-looking statements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

StillCanna Begins Hemp Initiative in Poland

Vancouver, British Columbia–(Newsfile Corp. – April 30, 2019) – StillCanna Inc. (CSE: STIL) (“STIL” or the “Company”) is pleased to announce it has begun its agricultural initiatives in Poland to farm over 1,500 hectares of its propriety high CBD content hemp varietal.

StillCanna has ordered and anticipates delivery in July of special harvesters and conveyors with proprietary dryers to make the harvest easy and efficient. The high-tech equipment is capable of speeds up to 15km per hour with a special four and a half meter wide cutting device. It’s estimated that the Company’s 2019 harvest will produce over 16 million grams of pure CBD. As our proprietary strain of hemp has a gestation period of 45 days, the Company is considering planting two crops on a number of its properties to increase its CBD production capabilities for 2020.

The Company anticipates breaking ground in May for its new CBD refinement facility in Poland, which is expected to cost approximately $6 million to complete its development. The facility is designed to have the capacity to initially produce up to 40 million grams of CBD annually with the ability to further build out the facility to increase production as necessary.

“Spring is an exciting time for global agriculture and StillCanna,” explained Jason Dussault, Chief Executive Officer of StillCanna. “The expansion of our EU footprint into Poland is yet another milestone in the implementation of our business initiatives. With over 20 years experience in hemp cultivation, we look forward to meeting the ever increasing demand for quality CBD from our fields and facilities.”

The Company also announces that it has engaged Native Ads Inc. to provide and manage a comprehensive digital media marketing campaign for the Company.

The Company has entered into an eight week programmatic digital advertising campaign for an approximate cost of one hundred thousand dollars for digital advertising, paid distribution, media buying and content creation. Neither Native Ads nor any of its directors and officers own any securities of the Company.

About StillCanna Inc.

StillCanna Inc. (CSE: STIL) www.stillcanna.com is a Canadian early-stage life sciences company focused on large scale CBD production in Europe. The company believes that its proprietary intellectual property allows it to extract CBD more efficiently and at a lower cost. The company has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly BioSciences LLC, a United Kingdom-based supplier of CBD. Upon the completion of the Olimax transaction, StillCanna will be one of the largest processor and providers of market ready CBD in Europe.

On Behalf of the Board,
Joel Leonard,
Chief Financial Officer and Director
E-mail: joel@stillcanna.com

The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release.

Cautionary Note Regarding Forward Looking Statements: This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the anticipated delivery in July of the harvesters and conveyors, the Company’s anticipated 2019 CBD yield of 16 million grams, the anticipated timeline of May for beginning construction of a CBD extraction facility in Poland, and the anticipated level of production at the planned CBD extraction facility in Poland and its anticipated cost. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the harvesters and conveyors will be delivered in July, the Company’s will have a 2019 CBD yield of 16 million grams, the construction of a CBD extraction facility in Poland will begin in May, and the level of production at the planned CBD extraction facility in Poland and its anticipated cost will be as anticipated by the Company’s management. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements. Such risk factors may include, among others, that the harvesters and conveyors will not be delivered in July, the Company’s will not have a 2019 CBD yield of 16 million grams, the construction of a CBD extraction facility in Poland will not begin in May or at all, and the level of production at the planned CBD extraction facility in Poland and its anticipated cost will not be as anticipated by the Company’s management. Readers are cautioned not to place undue reliance on forward-looking statements. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.